Aquaculture Vaccines Have Become a Billion-Dollar Animal Health Market and MSD's Acquisition Proved It

The Industry That Stopped Using Antibiotics

Norwegian salmon farming's transition from one of the highest antibiotic-using animal production systems in the world to one that uses virtually no antibiotics is the most commercially significant demonstration of what aquaculture vaccination can achieve at industry scale. In the 1980s, Norwegian salmon farms used antibiotics at levels that created the drug resistance concerns that regulators and health authorities now address in terrestrial livestock production, with antibiotic use in Norwegian salmon farming peaking at approximately fifty metric tonnes annually in 1987. The commercial deployment of injectable salmon vaccines against the bacterial diseases vibriosis and furunculosis, the two bacterial infections whose treatment had driven Norwegian salmon antibiotic use, reduced antibiotic consumption in Norwegian salmon farming by over ninety-nine percent within a decade of widespread vaccine adoption, demonstrating at commercial scale that vaccination could replace antibiotic treatment as the primary disease management tool in intensive aquaculture. The salmon farming industry's antibiotic use reduction was not primarily a regulatory achievement but a commercial one: the vaccines were more cost-effective than antibiotic treatment, they reduced mortality and improved farm profitability, and the growing premium that antibiotic-free seafood commanded in European retail markets created the additional commercial incentive that accelerated adoption beyond what disease management economics alone would have driven.

The global aquaculture vaccine market, valued at approximately five hundred million dollars in 2026 and growing at nearly nine percent annually toward a projected one billion two hundred million dollars by 2036, reflects the expansion of the vaccination model beyond Norwegian salmon to the broader global aquaculture industry whose diverse species, geographies, and disease challenges create both the commercial opportunity and the technical complexity that vaccine developers must address. Salmon remains the dominant species segment, accounting for approximately thirty-nine percent of aquaculture vaccine sales in 2026, because the Norwegian and Chilean salmon farming industries whose integration of vaccination into standard operating procedure have created the established commercial market that accounts for the majority of current aquaculture vaccine revenue. The market's growth trajectory is driven by the expansion of vaccination in tilapia, shrimp, seabass, seabream, and trout farming operations in Asia, the Middle East, and Latin America whose disease-driven mortality costs create the economic case for vaccination and whose antibiotic resistance concerns and export market access requirements are creating the regulatory pressure that accelerates vaccination adoption.

MSD's $1.3 Billion Acquisition and What It Signals

Merck Animal Health's acquisition of Elanco Animal Health's aquaculture business for $1.3 billion, completed in 2025, is the most commercially significant single transaction in the aquaculture animal health sector and the clearest signal that the major animal health companies assess the aquaculture market's long-term growth potential as sufficient to justify a premium acquisition price. Elanco's aquaculture portfolio, which included vaccines, anti-parasitic treatments, nutritional products, and manufacturing facilities in Canada, Vietnam, and a research centre in Chile, was built primarily through Elanco's own acquisition history in the aquaculture animal health sector. Merck Animal Health's acquisition creates the animal health company with the broadest aquaculture product portfolio, combining its existing aquaculture vaccine and treatment business with Elanco's portfolio to create a combined aquaculture animal health capability that no competitor currently matches in geographic coverage, species range, and product breadth. The strategic logic of the acquisition is the combination of the established salmon vaccination market, whose recurring revenue is anchored in Norwegian and Chilean salmon farming's annual vaccination programmes, with the growth optionality of the developing tilapia, shrimp, and warm-water species vaccination markets whose adoption of vaccination as standard practice is at an earlier stage than salmon.

Zoetis, the world's largest animal health company whose pharmaceutical origins in Pfizer's animal health division create the largest global sales infrastructure in the animal health sector, competes in aquaculture vaccines through its PHARMAQ brand, whose acquisition from a Norwegian aquaculture vaccine specialist in 2015 for $765 million established Zoetis as the first major pharmaceutical company to make a significant aquaculture vaccine acquisition. PHARMAQ's salmon vaccine portfolio and its Norwegian industry relationships create the aquaculture vaccine business that Zoetis has built on through continued product development in salmon, trout, and other cold-water species. The Zoetis-Merck Animal Health competitive dynamic in aquaculture vaccines mirrors their competition in terrestrial livestock vaccines but in a market segment whose growth rate is substantially higher and whose consolidation is less advanced, creating the commercial opportunity for technology and distribution advantages to translate more directly into market share gains than in the mature livestock vaccine market.

Delivery Innovation and the Species Expansion

The aquaculture vaccine market's expansion beyond salmon into warm-water species farming requires the development of vaccination delivery methods that differ from the intraperitoneal injection that is standard for salmon vaccination in Norway and Chile. Salmon vaccination by injection is economically practical because the salmon farming operations in Norway and Chile process millions of fish through hatchery vaccination programmes whose logistics allow individual fish handling at the smolt stage before sea transfer. Tilapia and shrimp farming operations in Asia and Latin America whose production volumes and fish sizes create the mass handling requirements that individual injection cannot practically address require immersion vaccination, oral vaccination through feed-delivered antigens, or the spray vaccination approaches that allow vaccination without individual fish handling. The technical challenge of achieving protective immunity through non-injection delivery routes whose antigen delivery to the fish immune system is less efficient than direct injection requires higher antigen doses, improved adjuvants, and often multiple vaccination events whose total cost and labour requirement must still compare favourably with the disease treatment costs that vaccination prevents.

Top 10 Companies in Aquaculture Vaccines Globally

1. MSD Animal Health (Merck): World's largest aquaculture animal health company following its $1.3 billion Elanco aqua acquisition; its combined salmon, trout, and warm-water species vaccine portfolio and its manufacturing in Canada, Vietnam, and Chile create the most geographically and commercially complete aquaculture vaccine business in the global animal health industry.
2. Zoetis (PHARMAQ): Global animal health company with the PHARMAQ aquaculture vaccine brand acquired from Norwegian specialists; its salmon vaccine portfolio and its Norwegian industry relationships create the premium aquaculture vaccine commercial position whose competition with MSD Animal Health defines the commercial dynamics of the salmon vaccination market.
3. Benchmark Holdings: UK aquaculture genetics, health, and nutrition company with aquaculture vaccine development capabilities; its cleaner fish biological sea lice control and its vaccine pipeline create the integrated aquaculture health company position whose combination of genetics, health products, and nutrition serves the salmon farming operations whose disease management requires solutions across multiple health dimensions simultaneously.
4. HIPRA: Spanish animal health company with aquaculture vaccine products for Mediterranean fish species including seabass and seabream; its European aquaculture market position and its warm-water fish vaccination experience create the aquaculture vaccine commercial presence in the Mediterranean and Southern European aquaculture markets whose species diversity differs from the Northern European salmon focus.
5. Elanco Animal Health: US animal health company that sold its aquaculture business to MSD while retaining terrestrial species focus; its former aquaculture portfolio's $1.3 billion valuation reflects the commercial value of the aquaculture animal health market that Elanco chose to monetise rather than invest in further as its strategic priority shifted toward companion animal and terrestrial livestock markets.
6. Vaxxinova: Dutch aquaculture vaccine company with autogenous and commercial vaccine manufacturing for aquaculture species; its autogenous vaccine capability that produces farm-specific vaccines against the specific pathogen strains infecting individual farms creates the customised aquaculture vaccination service that large integrated salmon farming operations use when commercial vaccines do not address the specific pathogen variant causing their disease challenge.
7. Phibro Animal Health: US animal health company with aquaculture health products including vaccines for warm-water species; its tilapia and shrimp health product development and its presence in the Latin American and Asian aquaculture markets create the warm-water species animal health commercial position whose growth reflects the aquaculture vaccine market's geographic and species expansion.
8. Virbac: French animal health company with aquaculture vaccine products in its animal health portfolio; its global animal health distribution network and its aquaculture health product development create the mid-sized animal health company position in the aquaculture vaccine market whose growth is attracting animal health companies beyond the specialist aquaculture vaccine developers.
9. Centrovet: Chilean aquaculture vaccine company serving the Chilean salmon farming industry; its proximity to the world's second largest salmon farming industry and its local regulatory relationships create the regional aquaculture vaccine commercial position that supplies the Chilean market whose disease challenges differ sufficiently from Norwegian conditions to require locally validated vaccine formulations.
10. Ridgeway Biologicals: UK aquaculture vaccine specialist with fish vaccine products for trout and other UK farmed species; its UK aquaculture vaccine manufacturing and its product development for the Northern European trout and salmon farming markets create the specialist aquaculture vaccine position that the larger animal health companies have consolidated around through acquisition.